Zacks Investment Research upgraded shares of IntelGenx Technologies (OTCMKTS:IGXT) from a sell rating to a hold rating in a research report released on Thursday.

According to Zacks, “IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The Company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastro-intestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. The Company’s research and development pipeline includes products for the treatment of osteoarthritis pain management, hypertension and smoking cessation. “

Other analysts have also issued research reports about the company. HC Wainwright set a $2.00 target price on IntelGenx Technologies and gave the company a buy rating in a report on Friday, November 9th. Maxim Group restated a buy rating and issued a $2.00 price objective on shares of IntelGenx Technologies in a report on Friday, November 9th. Finally, ValuEngine lowered IntelGenx Technologies from a buy rating to a hold rating in a research note on Wednesday, December 12th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus target price of $1.58.

IGXT stock traded up $0.01 on Thursday, reaching $0.53. 686,287 shares of the company’s stock were exchanged, compared to its average volume of 231,997. IntelGenx Technologies has a twelve month low of $0.43 and a twelve month high of $1.83. The firm has a market capitalization of $49.53 million, a PE ratio of -13.13 and a beta of 1.42. The company has a debt-to-equity ratio of 17.43, a current ratio of 1.41 and a quick ratio of 1.41.

IntelGenx Technologies (OTCMKTS:IGXT) last announced its quarterly earnings data on Thursday, November 8th. The company reported ($0.04) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($0.01). IntelGenx Technologies had a negative return on equity of 443.21% and a negative net margin of 325.81%. The business had revenue of $0.70 million for the quarter, compared to analyst estimates of $0.20 million. Equities research analysts expect that IntelGenx Technologies will post -0.14 earnings per share for the current fiscal year.

IntelGenx Technologies Company Profile

IntelGenx Technologies Corp., a drug delivery company, develops novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company's products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2012 for schizophrenia; and INT0043/2015 to treat cognitive impairment and Alzheimer's disease.

Featured Article: Bond

Get a free copy of the Zacks research report on IntelGenx Technologies (IGXT)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for IntelGenx Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelGenx Technologies and related companies with's FREE daily email newsletter.